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Abstract: The pharmacodynamic properties of fluvoxamine maleate include the modulation 
of different populations of serotonergic, dopaminergic, and sigma receptors and/or transporters, 
a complex pattern of activity that may account for its efficacy in the treatment of obsessive-
compulsive disorder (OCD). Nevertheless, its pharmacokinetic profile and its pattern of 
side effects may hinder a rapid dose escalation, a therapeutic strategy that might be utterly 
desirable in patients with OCD. In preclinical studies, the maximum plasma concentration and 
bioavailability of an extended-release (CR) formulation of fluvoxamine were, respectively, 
38% and 16% lower than those of the standard (ie, non-CR) formulation. Recently, the US 
Food and Drug Administration approved the fluvoxamine CR formulation for the treatment of 
OCD in adults. This approval was based on the results of a double-blind, placebo-controlled 
study with 253 OCD patients in which fluvoxamine CR showed a consistently earlier onset of 
therapeutic effects than other selective serotonin reuptake inhibitors, as reported in previous 
studies. The use of the CR formulation of fluvoxamine allowed a particularly aggressive dosing 
strategy at the beginning of the titration phase, ie, treatment could be started with a single dose 
of fluvoxamine CR 100 mg at bedtime, while keeping the occurrence of side effects and the 
rate of compliance at levels comparable to those reported for the use of immediate-release 
fluvoxamine.
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Introduction
Fluvoxamine maleate is a selective serotonin reuptake inhibitor (SRI) that belongs to a 
distinct chemical series: the 2-aminoethyl oxime ethers of aralkylketones.1 Fluvoxamine 
maleate is structurally unrelated to other selective SRIs and to clomipramine. It is 
chemically designated as 5-methoxy-4´-(trifluoromethyl) valerophenone-(E)-O-
(2-minoethyl) oxime maleate (1:1). It does not have an asymmetric carbon in its 
structure and therefore does not exist as optical isomers. For this reason, the potentially 
confounding issue of stereoisomerism does not arise with fluvoxamine.2
Clinical trials with immediate-release (IR) formulations of fluvoxamine in 
depression started in the 1970s and marketing approval was first obtained in Switzerland 
in 1983. Fluvoxamine IR started to be systematically tested in the treatment of 
obsessive-compulsive disorder (OCD) in the US in the late 1980s3 and gained US Food 
and Drug Administration (FDA) approval by the end of 1994. Recently, an extended-
release (CR, controlled-release) formulation of fluvoxamine was approved by FDA 
for the treatment of social anxiety disorder (SAD) and OCD in adults. Fluvoxamine 
CR incorporates Spheroidal Oral Drug Absorption System [SODAS(R)] technology, Neuropsychiatric Disease and Treatment 2009:5 302
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a method designed to minimize peak-to-trough plasma level 
fluctuations over a 24-hour period.
In this report, we aimed to critically review the phama-
codynamics, pharmacokinetics, efficacy, and tolerability of 
fluvoxamine in general, and of its CR formulation in particu-
lar, in the context of the treatment of patients with OCD.
Pharmacodynamics of fluvoxamine
The mechanism of action of fluvoxamine maleate in OCD 
is thought to involve serotonin reuptake inhibition in brain 
neurons. Fluvoxamine was shown to be a potent inhibitor of 
the serotonin reuptake transporter in preclinical studies, both 
in vitro and in vivo. Although there is some variability across 
studies, fluvoxamine appears to be a more potent inhibitor of 
in vitro serotonin reuptake than fluoxetine, but less powerful 
than paroxetine, sertraline, citalopram, and escitalopram.1,4 
Among the SRIs, fluvoxamine is one of the weakest inhibi-
tors of norepinephrine and dopamine reuptake.1 In in vitro 
studies, fluvoxamine maleate had no significant affinity for 
histaminergic, adrenergic, or muscarinic receptors, which 
are responsible for the various sedative, cardiovascular, and 
anticholinergic side effects commonly observed during treat-
ment with many psychotropic drugs. We will now discuss 
the putative pathways through which fluvoxamine leads to 
symptom improvement of patients with OCD, including 
the modulation of serotonergic, dopaminergic, and sigma 
transporters or receptors.
Serotonergic receptors
Only high doses of potent SRIs, such as clomipramine, 
fluvoxamine, fluoxetine, sertraline, paroxetine, citalopram, 
and escitalopram, are consistently effective in the treatment of 
OCD, particularly when administered for at least 12 weeks.5 
Furthermore, when patients with OCD who were successfully 
treated with clomipramine were switched in a double-blind 
fashion to desipramine, a selective noradrenergic reuptake 
inhibitor, they frequently relapsed.6 In the same vein, the 
adding of desipramine to the therapeutic scheme of OCD 
patients did not lead to any additional improvement.7 It has 
thus been argued that the anti-OCD effect of the SRIs results 
largely from the inhibition of the serotonin reuptake process, 
rather than from a non-specific antidepressant mechanism.8,9 
Indeed, several drug trials and meta-analytic studies have 
shown that the anti-OCD effect of SRIs is independent from 
the presence of depression.10,11
Recently, El Mansari and Blier12 argued that the delayed 
therapeutic response to high doses of SRI in OCD is congru-
ent with the time course of the desensitization of terminal 
5-HT1D receptors and of the increase in serotonin release 
in orbitofrontal cortex (OFC). They further hypothesized 
that enhanced serotonin release in the OFC results both in 
a decrease of the sensitivity of 5-HT1A receptors and in an 
activation of normosensitive postsynaptic 5-HT2-like recep-
tors, a biological cascade that could underlie the therapeutic 
actions of SRIs in OCD. This model is further supported by 
the serendipitous beneficial effect in OCD of some halluci-
nogens with 5-HT2 agonistic properties. Further, while low 
doses of the 5-HT2 antagonist risperidone has been shown 
to exert a positive therapeutic effect in SRI-resistant OCD 
patients, high doses of clozapine or risperidone cause an 
exacerbation of OCD symptoms, probably due to the antago-
nism of 5-HT2 receptors in OFC.12 Accordingly, Moresco 
et al13 found that fluvoxamine increased the in vivo binding 
of fluoro-ethyl-spiperone, a high affinity 5-HT2 serotonin 
receptor antagonist, in the frontal and occipital cortex of nine 
patients with major depressive disorder.
Molecular neuroimaging studies suggest that even small 
doses of fluvoxamine may exert significant serotonergic 
effects. For example, Suhara et al14 observed that a dos-
age as low as 50 mg/day of fluvoxamine maleate, either 
administered as a single dose or over a 6-month period, was 
associated with approximately 80% of occupancy of the 
serotonin transporters. In a prospective study, Takano et al15 
performed positron emission tomography scans before and 
5 hours, 26 hours, and 53 hours after the administration of 
50 mg of fluvoxamine to 6 healthy male volunteers. Mean 
serotonin transporter occupancies were 72.9% ± 4.9% at 
5 hours, 50.3% ± 11.0% at 26 hours, and 24.7% ± 15.3% at 
53 hours. Taken together, these findings suggest that while 
in low doses fluvoxamine occupies a significant percentage 
of serotonin transporters, in doses higher than 50 mg/day, 
like the ones that are usually required for the treatment of 
OCD, it likely recruits also other neurotransmitter systems 
or receptors.
Dopaminergic receptors
It is likely that different SRIs (including fluvoxamine) and 
dopaminergic antagonists have similar effects on certain 
neurobiological systems. In a pharmacological fMRI study 
conducted by Takahashi et al16 both fluvoxamine and sulto-
pride, a D2 receptor antagonist, attenuated the activity 
in the amygdala of healthy volunteers during exposure 
to unpleasant pictures, although the two treatments had 
slightly different modulatory effects on other components 
of the neural circuit of emotional processing. Unlike suto-
pride, fluvoxamine reduced activation in the orbito-frontal Neuropsychiatric Disease and Treatment 2009:5 303
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cortex (OFC), basal ganglia, and insula and induced greater 
activation in the temporal and parietal cortex.
Indeed, some authors have debated whether fluvoxamine 
and other SRIs exert their antiobsessional effects solely 
through an increase in the levels of serotonin or by an ultimate 
regulation of dopaminergic receptors.17 Accordingly, in a 
PET study, Moresco et al18 found that fluvoxamine treat-
ment increased the availability of dopaminergic type 2 (D2) 
receptors in the dorsal and ventral striatum of patients with 
OCD who responded to treatment. Of note, after a 12-week 
treatment, responders had mean binding potential values 
closer to those of normal volunteers, while the non-responder 
patients did not show increases in binding potential values 
in the dorsal part of the basal ganglia. Therefore, there is 
some evidence suggesting that fluvoxamine is able to modify 
the dopaminergic system, in general, and the availability of 
striatal dopamine D2 receptors, in particular, in patients with 
OCD. In light of these results, the increase in the availability 
of receptors may be consequent to the reduction of dopamine 
concentration induced by fluvoxamine and other SRIs.19
Sigma receptors
Sigma receptors are a unique set of proteins (σ1 and σ2) 
located in different neurons throughout the brain, particularly 
within their endoplasmic reticulum (ER).20 While the func-
tions of σ2 receptors are not well understood, the occupancy 
of σ1 receptors by its agonists causes translocation of this 
receptor from the ER to peripheral areas (membranes) of 
neurons, where σ1 regulates ion channels and the release of 
glutamate, dopamine, serotonin, norepinephrine, and acetyl-
coline, among other neurotransmitters.21
In animal studies, fluvoxamine, best known for its 
serotonin-reuptake inhibition, exhibits the strongest affinity 
and highest level of occupancy of σ1receptors among all 
anti-OCD agents.22 Indeed, in a study by Ishikawa et al23 
15 healthy individuals were submitted to two PET scans using 
the selective σ1receptor ligand [(11) C] SA4503 before and 
after a single dose of either fluvoxamine (50, 100, 150, or 
200 mg) or paroxetine (20 mg). While fluvoxamine bound to 
σ1 receptors in all brain regions in a dose-dependent manner, 
paroxetine did not, thus suggesting that, at therapeutic doses, 
σ1 receptors may be specifically involved in the mechanisms 
of action of fluvoxamine.
Further, Egashira et al24 found that fluvoxamine 
inhibits OCD-like behaviors in animal models (“marble-
burying behavior”). In this experimental paradigm, burying 
begins as an appropriate, investigative activity but, after 
frustrated investigation of a non-reactive stimulus object 
(ie, the marble), it persists as a compulsive stereotypy. This 
observation is in line with the view that compulsive behav-
iors result from one’s inability to achieve a sense of task 
completion.25 In the study by Egashira et al24 fluvoxamine 
inhibited burying behavior not only through the inhibition 
of the serotonin transporter, but also by means of the activa-
tion of σ1 receptors, while paroxetine, another SRI, inhibited 
this behavior mainly through the inhibition of the serotonin 
transporter. In fact, other selective σ1 receptors agonists, like 
the neurosteroids, were already found to inhibit other animal 
models of OCD.20
Pharmacokinetics of fluvoxamine
Fluvoxamine exhibits significant particularities in its phar-
macokinetics, including the lack of pharmacological activity 
of its metabolites, a low degree of binding to plasma proteins, 
and a high affinity for various cytochrome P450 (CYP) 
enzymes.26
After oral administration, fluvoxamine is nearly com-
pletely absorbed from the gastrointestinal tract, and the extent 
of the absorption is unaffected by the presence of food.2,27 
In a single-dose crossover study involving 28 healthy sub-
jects, fluvoxamine CR maximum plasma concentration and 
bioavailability were, respectively, 38% and 16% lower than 
those of the standard (ie, non-CR) formulation.28
In a multiple-dose proportionality study, fluvoxamine 
CR capsules were administered to 20 healthy volunteers 
with doses ranging from 100 mg/day to 300 mg/day. Steady-
state plasma concentrations were achieved within a week.28 
A study using fluorine-19 magnetic resonance spectroscopy 
showed that fluvoxamine IR concentrations reached steady 
state in the brain within approximately 1 month after consis-
tent dosing, which is substantially more rapid than previously 
observed for fluoxetine.29 It has been suggested that fluvox-
amine displays nonlinear steady-state pharmacokinetics, 
ie, disproportionately higher plasma concentrations with 
increased dosages.2,26,27 Since high doses of fluvoxamine 
are often required during the treatment of OCD,5 caution 
should be exercised when uptitrating its dose in order to 
avoid reaching toxic levels.
The mean apparent volume of distribution for fluvox-
amine is approximately 25 L/kg, suggesting extensive tissue 
distribution.28 The plasma protein binding of fluvoxamine 
has been reported to be circa 80%,27,30 the lowest value for 
any of the selectve SRI.26
Fluvoxamine undergoes extensive oxidative metabolism, 
most probably in the liver.2 The drug is metabolized to at least 
11 biotransformation products that are recovered in the urine Neuropsychiatric Disease and Treatment 2009:5 304
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after oral administration of radiolabeled fluvoxamine.27 Of 
the products that have been so far identified, none showed 
any significant pharmacologic activity.26,27 The specific cyto-
chrome P450 (CYP) isoenzymes involved in the metabolism 
of fluvoxamine are unknown.2,26 CYP2D6, which is crucially 
involved in the metabolism of paroxetine and fluoxetine, 
appears to play a clinically insignificant role in the metabo-
lism of fluvoxamine.2
The drug is excreted in the urine, predominantly as 
metabolites, with only negligible amounts (4%) of the 
active parent compound.2 Fluvoxamine shows a biphasic 
pattern of elimination with a mean terminal elimination half-
life of 12 to 22 hours after a single oral dose;2,26 this half-life 
is prolonged by 30% to 50% at steady state.2 After the oral 
administration of a single 100 mg capsule of fluvoxamine 
CR, the mean plasma half-life of fluvoxamine in healthy 
male and female volunteers was 16.3 hours.28 Fluvoxamine 
pharmacokinetics is substantially unaltered by increased age 
or renal impairment. However, its elimination is prolonged in 
patients with hepatic cirrhosis.2,27 For a comparison between 
the pharmacokinetics properties of different formulations of 
fluvoxamine, see Table 1.
In a study using fluorine-19 magnetic resonance spectros-
copy (19F MRS), the elimination half-lives of fluvoxamine 
in brain and plasma were determined to assess their inter-
dependence.31 In this study, the mean ratio of fluvoxamine 
brain elimination half-life to plasma half-life was 2.4, thus 
suggesting that fluvoxamine is eliminated from brain at a 
slower pace than from plasma.
Fluvoxamine inhibits oxidative drug metabolizing 
enzymes (particularly CYP1A2, and less potently, 
CYP3A4 and CYP2D6) and has the potential for clinically 
significant drug interactions.2 In the management of OCD, 
an array of different augmentation strategies may be 
employed in patients who exhibit only partial response to 
selective SRIs, including the use of clomipramine or of 
atypical antipsychotics as an add-on therapy.5 Clinicians 
should take into account the fact that fluvoxamine may 
lead to increased plasma levels of the augmentation 
drugs, either by inhibiting the CYP 1A2 (ie, haloperidol, 
olanzapine, and clomipramine) or the CYP3A4 (ie, 
haloperidol, pimozide, risperidone, quetiapine, and 
clomipramine). Depending on the ability of the prescriber, 
these interactions may lead to either an increased efficacy 
or to toxicity.28,32,33
Efficacy of fluvoxamine IR in OCD
The efficacy of fluvoxamine in the management of OCD has 
been confirmed by a number of randomized, double-blind, 
controlled studies, making it the first selective SRI to be 
registered for this clinical indication.34 Placebo-controlled 
studies conducted over 6 to 12 weeks have consistently 
shown a significantly greater response to fluvoxamine 
IR (100–300 mg/day) as assessed by the Yale-Brown 
Obsessive-Compulsive Scale (Y-BOCS), the National 
Institute of Mental Health Obsessive-Compulsive 
(NIMH-OC) scale, and the CGI scales.35–38 According to 
a review on the studies of fluvoxamine IR in OCD, no 
significant correlation between plasma fluvoxamine levels 
and treatment response was found.1 There is some evidence 
from two early placebo-controlled studies suggesting 
that fluvoxamine significantly augments the efficacy of 
behavior therapy.39,40
The majority of double-blind, active treatment-
controlled studies of fluvoxamine have been conducted 
with clomipramine, another SRI.41–45 All these studies 
found that fluvoxamine and clomipramine were equally 
effective for the treatment of OCD. Although meta-analytic 
Table 1 Comparison between the pharmacokinetic parameters of IR and CR formulations of fluvoxamine
Fluvoxamine IR Fluvoxamine CR
Bioavailability
Tmax 6 h 15 h
Cmax 41.88 ng/mL (±18.99) 25.78 ng/mL (±15.66)
AUC(0–inf) 959.33 ng × h/mL (±520.71) 806.31 ng × h/mL (±450.92)
Volume of distribution 25 L/kg 25 L/kg
Plasma protein-binding 80% 80%
Metabolism Deamination and oxidative demethylation Deamination and oxidative demethylation
Plasma half-life 15.9 h 16.3 h
Excretion renal renal
Abbreviations: ir, immediate release; Cr, extended release;   Tmax, time to maximum plasma concentration;  Cmax, maximum plasma concentration;   AUC (0–inf), area under the curve.Neuropsychiatric Disease and Treatment 2009:5 305
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studies suggest that there is a small advantage for 
clomipramine over fluvoxamine and other selective SRI, 
they generally confirmed that its lower tolerability, as will 
be discussed below, makes clomipramine a second-line 
medication.10,11,46
Fluvoxamine is the only selective SRI that has been 
tested so far against a noradrenaline reuptake inhibitor, 
desipramine, in the acute treatment of OCD.8 Both the rate 
of response and the change from baseline to endpoint in 
YBOCS scores were significantly greater with fluvoxamine 
than with desipramine. Long-term maintenance treatment 
with fluvoxamine seems to reduce the risk of relapse, and 
there is some indication that lower dosages may also be 
effective, although only small scale studies have been 
conducted to date.47,48
Few neuroimaging studies have investigated the pres-
ence of predictors of response to fluvoxamine among 
patients with OCD. Rauch et al49 found that lower regional 
cerebral blood flow (rCBF) values in OFC and higher 
rCBF values in posterior cingulate cortex predicted bet-
ter treatment response to fluvoxamine among patients 
with contamination-related OCD. This same pattern of 
associations was present regardless of whether the imag-
ing data were acquired during a provoked or neutral state. 
Conversely, Ho Pian et al50 reported that levels of rCBF 
decreased significantly in the left caudate nucleus and in 
the left and right putamen in both responders and non-
responders to treatment with fluvoxamine. However, only 
in responders a significant decrease in rCBF was found in 
the right thalamus. Taken together, these findings suggest 
that the pattern of activity of structures from the cortico-
striato-thalamo-cortical circuit may help predict individuals 
who will respond to treatment with fluvoxamine, a finding 
that is consistent with the results obtained in prediction 
studies with other SRIs.
Efficacy of fluvoxamine CR in OCD
Patients with OCD often require long-term treatment. 
However, discontinuation of drug treatment remains a 
significant hurdle in the management of patients with OCD, 
leading to relapse in the majority of cases, even when 
treatment has been administered for more than 2 years.51 
This is particularly true when drug treatment has not been 
combined with cognitive-behavioral therapy.52 Therefore, 
not only substantial symptom relief, but also better drug 
tolerability and a convenient dosing regimen are equally 
important for increasing treatment compliance of patients 
with OCD.53
Controlled-release formulations of newer antidepressants, 
including fluvoxamine, could lead to less short-term side 
effects and facilitate a more rapid titration regimen, an 
approach that could hasten treatment response in OCD.54 
In addition, by producing more stable blood levels, such 
CR formulations would reduce the large swings in plasma 
levels observed between doses and decrease the frequency 
of administration required to maintain therapeutic levels.55 
Recently, a new CR formulation of fluvoxamine maleate, 
fluvoxamine CR, with peculiar pharmacokinetic features, 
has been developed, tested, and approved by the FDA for 
the treatment of adult patients with OCD.
In a multicenter randomized, double blind, 12-week long 
placebo-controlled study, Hollander et al53 compared the 
efficacy and safety of a flexible dosing of fluvoxamine CR 
(100–300 mg/day) to placebo in the treatment of patients 
with OCD. In this study, a particularly aggressive dosing 
strategy was adopted at the beginning of the titration 
phase: subjects who were randomly assigned to receive 
fluvoxamine CR began with a bedtime dose of 100 mg and 
were progressively titrated, in weekly increments of 50 mg 
(if tolerated), to a final bedtime dose ranging from 100 to 
300 mg/day over the first 6 weeks of treatment; thereafter, 
the dose remained constant for the duration of the double-
blind period. The starting dose was twice the dose usually 
employed in earlier comparable studies of fluvoxamine IR 
in OCD. Hollander et al53 demonstrated that fluvoxamine 
CR was significantly superior to placebo in all efficacy 
measures, including the change from baseline to endpoint 
in Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) 
and Clinical Global Impression (CGI)-severity scores, 
as well as CGI-improvement scores and responder rate 
at endpoint. Unfortunately, this study did not report any 
attempt to establish the therapeutic plasma concentration 
range of fluvoxamine.
The magnitude of the decreases from baseline to end-
point in the Y-BOCS total score (fluvoxamine CR 8.5 ± 0.7 
[31.7% change] vs placebo 5.6 ± 0.7 [21.2% change]) and 
CGI severity score (fluvoxamine CR 2.7 ± 0.1 vs placebo 
3.2 ± 0.1) for subjects treated with fluvoxamine CR in this 
study were similar to those observed in previous studies with 
fluvoxamine IR,37,38 fluoxetine,56 paroxetine,57 and sertra-
line.58 Also, the rates of remission were significantly higher 
in the fluvoxamine CR-treated patients than in the placebo 
group (44 versus 31% and 18 versus 8%, given Y-BOCS 
threshold values  16 and 8, respectively). Of interest, 
while the differences between fluvoxamine IR and placebo 
emerged from the 4th to the 10th week of treatment in early Neuropsychiatric Disease and Treatment 2009:5 306
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studies of patients with primary OCD,35–38 the differences 
between fluvoxamine CR and placebo in Hollander et al37 
study achieved statistical significance at the second week 
of treatment both in the primary efficacy variable (ie,the 
Y-BOCS total score) and in the secondary efficacy variables 
(ie, CGI-score and responder rate). In other words, fluvox-
amine CR showed a consistent earlier onset of therapeutic 
effects across different efficacy parameters when compared 
with the findings of previous studies involving other selec-
tive SRI. Unfortunately, however, no discontinuation study 
of fluvoxamine CR in OCD was conducted so far. Therefore, 
no information regarding the percentage and speed of relapse 
is available.
Hollander et al53 proposed several possible explanations 
for the earlier onset of action of fluvoxamine CR. First, 
because fluvoxamine CR exhibits less circadian fluctuation 
in plasma levels (peak to trough concentration), patients 
may benefit from having drug concentrations that are 
above the minimally therapeutically effective one during 
most of the day. Second, because fluvoxamine CR has a 
lower maximal concentration compared with fluvoxamine 
after the same dosing, subjects could be started at a higher 
dosage of fluvoxamine CR but still enjoyed a similar 
tolerability profile, akin to a pulse loading strategy with 
clomipramine.59 Third, the more rapid dose escalation of 
fluvoxamine CR compared with conventional fluvoxamine 
may allow for earlier effects on gene expression, as has 
been suggested in pulse-loading intravenous treatment 
studies in OCD.59
The earlier response to fluvoxamine CR observed in 
patients with OCD must be viewed with caution. For 
example, in the study by Westenberg et al60 who investigated 
the effectiveness of this formulation in patients with SAD, 
fluvoxamine CR was titrated in a similar fashion to that 
adopted in the OCD study53 but differed from placebo only 
after the fourth week of treatment.
In fact, since both disorders were previously found to 
exhibit similar patterns of response to selective SRIs, we can 
only speculate about the reasons underlying this apparently 
inconsistent finding. First, the mean endpoint dose of fluvox-
amine CR was 271 mg/day in the OCD study and 209 mg/day 
in the SAD study. Second, the Liebowitz Social Anxiety 
Scale, which was the primary efficacy variable in Westenberg 
et al59 study, may be less sensitive to early changes exhibited 
by patients with SAD than Y-BOCS is to changes shown by 
patients with OCD. Finally, there may be some unidentified 
differences other than the diagnoses between the samples 
recruited for these studies. One way or another, further 
controlled studies are needed to elucidate whether the earlier 
onset of action of fluvoxamine CR in OCD patients is also 
found in patients with other anxiety or mood disorders.
Tolerability of fluvoxamine CR
Fluvoxamine IR exhibits antiobsessional properties 
similar to those of other selective SRIs and clomipramine, 
but has a somewhat superior tolerability profile than 
clomipramine, particularly with respect to a lower 
incidence of anticholinergic effects and reduced cardiotoxic 
potential.37 However, gastrointestinal adverse effects are 
seen more frequently with fluvoxamine IR than with tricyclic 
antidepressants.2 Indeed, in controlled trials in OCD and 
depression, the most commonly reported side effects likely 
to be related to fluvoxamine IR (ie, whose incidence is 5% 
or greater and at least twice that for placebo) were nausea 
(40% in active drug vs 14% in placebo), somnolence (22% 
in active drug vs 8% in placebo) and insomnia (21% in active 
drug vs 10% in placebo).61
Reduced fluctuations in plasma concentration observed 
during treatment with fluvoxamine CR may be associated 
with fewer side effects. The tolerability of fluvoxamine CR 
has been studied in two controlled trials of social anxiety 
disorder (N = 579)60,62 and one trial of OCD (N = 124).53 
In general, adverse event rates were similar in the two data 
sets. As for fluvoxamine IR, the most commonly observed 
adverse events associated with the use of fluvoxamine 
CR for patients in social anxiety disorder were nausea 
(315%–47% vs 6%–15%), somnolence (22%–31% vs 
7%–10%), insomnia (31%–32% vs 11%–15%), and asthe-
nia (28% vs 13%).60,62 In both studies, no weight gain was 
observed for either treatment group, and at end point there 
were no differences between treatments on overall sexual 
function, as measured by the Arizona Sexual Experience 
Scale.60,62 By the same token, the most commonly observed 
adverse events associated with the use of fluvoxamine CR 
and likely to be drug-related (incidence of 5% or greater and 
at least twice that for placebo) for patients with OCD were 
insomnia (35% vs 20%), nausea (34% vs 13%), somnolence 
(27% vs 11%), asthenia (25% vs 8%), diarrhea (18% vs 
8%), and anorexia (13% vs 5%).53
As seen in the above-mentioned studies, even though the 
fluvoxamine CR starting dose was higher (100 mg/day) and 
taken once daily, the profile of side effects associated with 
fluvoxamine CR remained roughly the same of those seen 
in early fluvoxamine IR studies, in which lower, divided 
doses were employed.37,38 In the fluvoxamine CR study 
in OCD patients, while a higher proportion of subjects in Neuropsychiatric Disease and Treatment 2009:5 307
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the active treatment group (19%) discontinued treatment 
due to adverse events (as compared to 6% of the placebo 
treatment group), the discontinuation rate was comparable 
to that observed in previous studies with other selective SRIs 
(including fluvoxamine IR studies). Of note, there was no 
significant weight gain with fluvoxamine CR. Finally, as 
is true for other selective SRIs, the therapeutic index (ratio 
of lethal to therapeutic dose) of fluvoxamine is high and, 
consequently, the risk of death with intentional overdosage 
appears to be relatively low.1
Conclusions
The pharmacokinetics of  different SRIs, including fluvoxamine 
IR, and the associated pattern of side effects hinder a rapid 
dose escalation, a strategy that may be desirable in the 
treatment of patients with OCD. The CR formulation of 
fluvoxamine allows a more aggressive dosing strategy at the 
beginning of the titration phase and results in a pattern of 
side effects and compliance that is roughly the same of those 
seen in fluvoxamine IR. Nevertheless, since there is no head-
to-head study comparing the efficacy of fluvoxamine CR to 
that of its IR formulation, it is not possible, at this point, to 
estimate differences in terms of treatment response between 
the two formulations.
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